Doxorubicin-induced cardiometabolic disturbances: what can we do?

[No abstract available]

Авторы
Avagimyan A. , Pogosova N. , Rizzo M. , Sarrafzadegan N.
Журнал
Frontiers in Clinical Diabetes and Healthcare
Издательство
Frontiers Media SA
Язык
Английский
Статус
Опубликовано
Ссылка
Внешняя ссылка
DOI
10.3389/FCDHC.2025.1537699
Номер
1537699
Том
6
Год
2025
Организации
  • 1 Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
  • 2 Isfahan Cardiovascular Research Centre, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  • 3 Sciences and Preventive Cardiology, National Medical Research Centre of Cardiology after Acad. E. I. Chazov, Moscow, Russian Federation
  • 4 Evidence-Based Medicine Department, Institute of Medicine, Patrice Lumumba Peoples' Friendship University of Russia (RUDN), Moscow, Russian Federation
  • 5 Cardiometabolic Medicine Department, University of Palermo, Palermo, Italy
Ключевые слова
cardiometabolic; chemotherapy; doxorubicin; glucose; GLUT; insulin resistance; metabolism; myocardium
Цитировать
ГОСТ MLA RIS BibTex
Поделиться

Другие записи